Search

Johnson and Johnson

Closed

SectorHealthcare

278.2 1.12

Overview

Share price change

24h

Current

Min

271.18

Max

280.92

Key metrics

By Trading Economics

Income

299M

5.5B

Sales

1.2B

25B

P/E

Sector Avg

31.057

56.659

EPS

2.9

Dividend yield

1.95

Profit margin

21.865

Employees

138,200

EBITDA

721M

9B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+3.86% upside

Dividends

By Acuity

Dividend yield

Sector Avg

1.95%

2.18%

Next Earnings

13 Oct 2026

Next Dividend date

8 Sept 2026

Next Ex Dividend date

24 Nov 2026

Market Stats

By TradingEconomics

Market Cap

22B

641B

Previous open

277.08

Previous close

278.2

News Sentiment

By Acuity

38%

62%

101 / 340 Healthcare

Johnson and Johnson Chart

Past performance is not a reliable indicator of future results.

Related News

2 Sept 2026, 23:06 UTC

News

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

1 Sept 2026, 20:01 UTC

Johnson & Johnson shares are higher today, reaching the upper end of their one-month trading range during the session. No specific news was identified.

31 Aug 2026, 23:06 UTC

News

Johnson & Johnson shares are higher in after-market trading following the announcement of an investor conference call on October 13, 2026, for third-quarter results.

29 Aug 2026, 00:01 UTC

News

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

28 Aug 2026, 20:08 UTC

Johnson & Johnson shares are higher during Friday's session, reflecting a modest gain since Thursday's close amid routine trading and rising Treasury yields.

27 Aug 2026, 23:01 UTC

Johnson & Johnson shares advanced in after-market trading, recovering from earlier volatility. Broader market context includes a decline in initial jobless claims.

26 Aug 2026, 23:06 UTC

Johnson & Johnson shares are lower during after-market hours, reflecting a decline since Wednesday's close amid broader market concerns over persistent inflation pressures.

25 Aug 2026, 23:06 UTC

Johnson & Johnson shares are lower in after-market trading, reflecting broader market trends and a decline in crude oil prices influencing investor sentiment.

24 Aug 2026, 19:06 UTC

Social Media
News

Johnson & Johnson's shares are higher today, recovering from earlier volatility and trading above its 20-day moving average near a one-month peak.

21 Aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-hours trading, maintaining a position above the 20-day moving average despite a slight pullback from earlier gains.

20 Aug 2026, 23:41 UTC

News

Johnson & Johnson shares are higher in after-market trading following operational sales growth and a raised full-year outlook amid recent FDA clearances for its bronchoscopy software.

19 Aug 2026, 19:32 UTC

News
Social Media

Johnson & Johnson shares advance as EVP Jennifer Taubert exercises options for 15,000 shares valued at $2.38 million and receives regulatory clearance for MONARCH QUEST 3 software.

18 Aug 2026, 23:56 UTC

Social Media

Johnson & Johnson returns the C-CAR039 program to AbelZeta, while discussions about a potential acquisition of Legend Biotech continue. Shares are roughly flat in after-market trading.

17 Aug 2026, 23:06 UTC

Johnson & Johnson's shares are roughly flat in after-market trading. The stock remains positioned above its 20-day moving average and near its one-month range.

14 Aug 2026, 19:46 UTC

Johnson & Johnson shares are lower as pharmaceuticals sub-sector weakness persists. The stock reached a session low earlier before recovering slightly.

13 Aug 2026, 19:21 UTC

Johnson & Johnson shares are higher, reflecting broader market gains amid stabilizing inflation pressures and a drop in crude oil prices.

12 Aug 2026, 23:26 UTC

Johnson & Johnson shares are lower in after-market trading, despite initially rising above Wednesday's close. The stock remains above its 20-day moving average.

11 Aug 2026, 19:26 UTC

Johnson & Johnson shares are lower today, influenced by a downturn in the Pharmaceuticals sub-sector. The stock has shown notable volatility during the session.

10 Aug 2026, 23:06 UTC

News

Johnson & Johnson will present at the Morgan Stanley Healthcare Conference on September 14, 2026. Shares are roughly flat in after-market trading.

8 Aug 2026, 00:02 UTC

Johnson & Johnson shares declined in after-market trading, retracing from a brief recovery and currently positioned at the midpoint of their one-month trading range.

7 Aug 2026, 23:41 UTC

Johnson & Johnson shares are lower in after-market trading, experiencing notable volatility with no specific news identified to explain the movement.

6 Aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market hours, following a session within its one-month trading range. No specific news was identified for the move.

5 Aug 2026, 23:51 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance within their one-month trading range amid broader cautious market sentiment.

4 Aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting routine performance and stability amid broader market conditions.

3 Aug 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market trading, supported by stronger-than-expected manufacturing PMI data for July that signals sector growth.

1 Aug 2026, 00:01 UTC

Johnson & Johnson shares gained in after-market trading, reflecting a cumulative return of 0.35% since Friday's close, despite no specific news driving the movement.

31 Jul 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, showing notable strength amid mixed performance in U.S. markets with no specific news identified.

30 Jul 2026, 18:22 UTC

News
Event

Johnson & Johnson shares are lower amid concerns over a $1 billion acquisition of Firefly Bio and a partnership with Sail Biomedicines, impacting future earnings.

29 Jul 2026, 21:41 UTC

News

Johnson & Johnson lowered its fiscal year 2026 adjusted EPS guidance to $10.86 to $11.01, contributing to a decline in after-market trading.

28 Jul 2026, 23:31 UTC

Johnson & Johnson shares are higher in after-market trading, remaining above their 20-day moving average after six consecutive daily gains.

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

3.86% upside

12 Months Forecast

Average 285.82 USD  3.86%

High 320 USD

Low 260 USD

Based on 17 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

14

Buy

3

Hold

0

Sell

Sentiment

By Acuity

101 / 340 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat